Medicinal cannabis is safe and effective in pain relief, and researchers are calling for the treatment to be properly established in our modern medical arsenal. A new special issue of the European Journal of Internal Medicine provides a comprehensive overview of current evidence for the use of cannabis and derived products in medicine, and calls for more research to improve the evidence base for its use.
African-Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European-Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center. They published the study results in the Feb. 22 online issue of the Journal of Clinical Endocrinology and Metabolism.
According to a panel of international experts, clinical trials of multimorbidity should measure and report, at minimum, quality of life, mortality, and mental health outcomes.
Diagnostic and treatment advances are helping patients with Duchenne muscular dystrophy live into their 30s and beyond, raising challenges in such areas as education, vocation, levels of independence, personal relationships, emotional health, and intimacy. To address these shifting circumstances, as well as reflect promising new treatment options, new guidelines aimed at physicians who care for DMD patients have recently been issued.
Among people with a type of hole in the heart, known as patent foramen ovale (PFO), those who received a medical device to close this opening after a stroke fared better after two years compared with those who received stroke-preventing medications alone.
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound healing, compared with those receiving a placebo, in a study presented at the American College of Cardiology's 67th Annual Scientific Session.
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in patients with acute coronary syndrome (ACS) who were randomly assigned to receive dual antiplatelet therapy (DAPT) for either six months or at least 12 months after receiving a drug-eluting stent.
The experimental drug andexanet was associated with control of serious bleeding in patients taking a common class of anticoagulants known as Factor Xa inhibitors, according to interim clinical trial results presented at the American College of Cardiology's 67th Annual Scientific Session. Millions of patients take Factor Xa inhibitors, which elevate the risk of serious bleeding.
The study enrolled 1,754 patients in 19 countries, 51 percent of whom were male, with an average age of 70 years. After an average follow-up of 16 months, 11 percent of patients treated with dabigatran experienced a MINS-related event, compared with 15 percent of patients who received a placebo. This translates to a 28 percent reduction in risk for patients receiving dabigatran.
A University of Colorado Cancer Center study published March 12 in the journal Developmental Cell suggests inhibiting molecule FOXO3a could increase effectiveness of autophagy-inhibitors, which have shown promise but little success in clinical practice.